AGGRASTAT® Injection Pre-mixed (HCPCS code J3246) is a clear, non-preserved, sterile solution premixed in a vehicle made iso-osmotic with 0.9% sodium chloride.
In 2021, Medicure Pharma reintroduced the AGGRASTAT® 5MG/100ML Bag (NDC: 25208-0002-01). It is the same concentration, ready-to-use- format, storage, and has the same stability properties and price as the AGGRASTAT® 5MG/100ML Vial (NDC: 25208-0002-03). The 5MG/100ML vial format will no longer be manufactured. The 5MG/100ML bag will replace the 5MG/100ML vial.
Product Format | Product Details | |||
---|---|---|---|---|
NDC | Concentration | Total Amount | ||
15 mL Bolus Vial | 25208-0001-04 | 250 mcg/mL | 3.75 mg/15 mL | |
100 mL Bag | 25208-0002-01 | 50 mcg/mL | 5 mg/100 mL | |
250 mL Bag | 25208-0002-02 | 50 mcg/mL | 12.5 mg/250 mL |
Wholesaler | Item Number | |||
---|---|---|---|---|
3.75 mg/15ml Pre-mixed Bolus Vial |
5 mg/100 ml Pre-mixed Bag |
12.5 mg/250 ml Pre-mixed Bag |
||
AmerisourceBergen Drug Corporation | 10169784 | 10261079 | 10040778 | |
Cardinal Health, lnc. | 5293881 | 4073318 | 4073334 | |
McKesson Corporation | 3590874 | 1469677 | 1480433 | |
Morris & Dickson Company, LLC | 856963 | 930917 | 859645 |
Store AGGRASTAT® at controlled room temperature, 25 °C (77 °F) with excursions permitted between 15–30 °C (59–86 °F). Do not freeze. Protect from light during storage.
Please download our Product Return and Replacement Form or email aggrastat@medicure.com to learn more.
Aggrastat® is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).
For additional information, refer to the full Prescribing Information.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.FDA.gov/medwatch
or call 1-800-FDA-1088.
* This website is intended for U.S. healthcare professionals only.